Comparative Pharmacology
Head-to-head clinical analysis: ANEXSIA 5 325 versus ROXICET.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANEXSIA 5 325 versus ROXICET.
ANEXSIA 5/325 vs ROXICET
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Hydrocodone is a semi-synthetic opioid agonist that binds to mu-opioid receptors in the CNS, inhibiting ascending pain pathways and altering pain perception. Acetaminophen is a para-aminophenol derivative with analgesic and antipyretic effects, primarily through central COX-2 inhibition and activation of descending serotonergic pathways.
Roxicet is a combination of oxycodone, a full mu-opioid receptor agonist, and acetaminophen, which inhibits cyclooxygenase (COX) enzymes, primarily in the central nervous system, to reduce pain perception and fever.
1-2 tablets orally every 4-6 hours as needed for pain; maximum 8 tablets per day.
1-2 tablets (oxycodone 5-10 mg/acetaminophen 325-650 mg) orally every 4-6 hours as needed for pain; maximum acetaminophen 4000 mg/day (3000 mg/day in high-risk patients).
None Documented
None Documented
Oxycodone: terminal half-life 3.2-4.3 hours (immediate-release); prolonged in hepatic impairment. Acetaminophen: terminal half-life 2-3 hours (therapeutic doses); prolonged in hepatic impairment or overdose.
Oxycodone: 3-5 hours (immediate-release); prolonged in hepatic/renal impairment. Acetaminophen: 2-3 hours.
Oxycodone: renal excretion of metabolites (conjugated and unconjugated) and parent drug; ~10% excreted unchanged. Acetaminophen: renal excretion of metabolites (glucuronide and sulfate conjugates); ~2-4% excreted unchanged.
Primarily renal (90% as glucuronide conjugates, <10% unchanged). Biliary/fecal excretion is minor (<5%).
Category C
Category C
Opioid Analgesic Combination
Opioid Analgesic Combination